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Abstract: Hypoxia is a non-physiological level of oxygen tension, a phenomenon common in a
majority of malignant tumors. Tumor-hypoxia leads to advanced but dysfunctional vascularization and acquisition of epithelial-to-mesenchymal transition phenotype resulting in cell mobility
and metastasis. Hypoxia alters cancer cell metabolism and contributes to therapy resistance
by inducing cell quiescence. Hypoxia stimulates a complex cell signaling network in cancer
cells, including the HIF, PI3K, MAPK, and NFĸB pathways, which interact with each other
causing positive and negative feedback loops and enhancing or diminishing hypoxic effects.
This review provides background knowledge on the role of tumor hypoxia and the role of the
HIF cell signaling involved in tumor blood vessel formation, metastasis, and development of
the resistance to therapy. Better understanding of the role of hypoxia in cancer progression will
open new windows for the discovery of new therapeutics targeting hypoxic tumor cells and
hypoxic microenvironment.
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Twenty-five percent of deaths in the United States are caused by cancer, and the number
of incidences increases due to population growth, prolonged life expectancy, and an
abundance of risk factors including smoking, a lack of activity, and obesity.1 A common
feature of most tumors is a low level of oxygen, called hypoxia, the severity of which
varies between tumor types (Table 1). In intensively proliferating and expanding tumor
tissue, oxygen demand is surpassed by oxygen supply, and the distance between cells
and the existing vasculature increases, hampering oxygen diffusion and creating even
more hypoxic milieu.2,3 It is generally accepted that the oxygen level in hypoxic tumor
tissues is poorer than the oxygenation of the respective normal tissues and on average
it is between 1%–2% O2 and below (Table 1). However, tumor oxygen level depends
on the initial oxygenation of the tissue, the size and stage of the tumor, the method of
oxygen measurement, and in which part of the heterogenic tumor tissue the measurement was performed (Table 1).4–7 Tissue normoxia, also known as physoxia, is the oxygenation in healthy tissues, which varies widely between the organs due to diversified
blood vessel network and metabolic activity. Oxygen concentration in humans ranges
between approximately 9.5% O2 in the renal cortex7 to 4.6% O2 in the brain with neurons
extremely sensitive to hypoxia.8–10 These oxygen values are far from the experimental in
vitro conditions. The oxygen concentration commonly used in the laboratory setting is
20.9% O2, which means that cell culture is performed in hyperoxic rather than physoxic
conditions of respective organs. In order to better understand principles of oxygenation
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Table 1 Comparison of the oxygenation in organs and respective tumors
Tissue/organ

Physoxia (median % O2)

Reference

Cancer

Hypoxia (median % O2)

Reference

Brain
Breast
Cervix (nullipara)
Kidney cortex
Liver
Lung
Pancreas
Rectal mucosa

4.6
8.5
5.5
9.5
4.0–7.3
5.6
7.5
3.9

8,9
6
4,6
7
125,126
127
128
130

Brain tumor
Breast cancer
Cervical cancer
Renal cancer
Liver cancer
Non-small-cell lung cancer
Pancreatic tumor
Rectal carcinoma

1.7
1.5
1.2
1.3
0.8
2.2
0.3
1.8

6,122
6,123
4,6
124
125,126
127
128,129
130

in vitro and in vivo, basic knowledge of the physics of gases
is required for newcomers in the hypoxia research field which
has been neatly described in a recently published review.11
Cancer cells respond differently to decreased oxygenation leading to cell death or cell survival which partially
depends on the time of exposure to hypoxia. The discrepancy
and lack of consistency in experimental oncology regarding
the definition of acute versus chronic hypoxia often with different biological consequences was thoroughly reviewed.12,13
In general, it is accepted that acute hypoxia is an abrupt and
brief exposure to short-term hypoxia which occurs when
blood vessel occlusion lasts for at least several minutes.14 It
is reversible and often leads to oxygen fluctuations called
cycling hypoxia. In acute hypoxia in vitro, cells are usually
exposed to continuous hypoxia between a few minutes and
up to 72 hours.12 Short-term hypoxia allows cells to survive in these adverse conditions by activating autophagy,
an apoptotic and metabolic adaptation of cells. Autophagy
is achieved by decreasing oxidative metabolism.15,16 On
the contrary, others have shown that cycling hypoxia led
to increased reactive oxygen species (ROS) production,
what contributed to tumor cell survival and progression.17,18
Moreover, both short- and long-term hypoxia was shown
to increase radio-resistance of cancer cells both in vitro17,19
and in vivo.17,20 In addition, acute hypoxia was associated
with more aggressive tumor phenotype through induction
of spontaneous metastasis.12,21,22
Enduring changes in blood flow and low oxygen
availability resulting in chronic hypoxia are especially
pronounced in larger tumors and contribute to long-term
cellular changes. In experimental settings, chronic conditions are considered when the cells are incubated in hypoxia
between a few hours and as long as several weeks.12 Longer
exposure to hypoxia is associated with high frequency of
DNA breaks, accumulation of DNA replication errors
since hypoxia hampers DNA repair systems including
homologous recombination and mismatch repair, potentially leading to genetic instability and mutagenesis.23–25 Of
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note, acute hypoxia also leads to genomic instability due to
delayed DNA damage response and rapid p53-dependent
apoptosis.26 It was suggested that cells lacking functional
p53 are more susceptible to genomic instability and potentially tumorigenesis if they experience reoxygenation after
acute exposure to hypoxia.26
Nonetheless, cycling hypoxia represents the situation of
oxygenation in tumor tissues. Oxygen fluctuation occurs at
irregular intervals in cancer with sporadic reoxygenation
periods due to dysfunctional tumor vascularity and heterogenic blood supply.27,28 Undoubtedly, both chronic and acute
hypoxic regions in tumors directly affect clinical responses to
therapy by influencing tumor growth, ability to metastasize,
and resistance to cell death.

Signaling pathways related
to tumor hypoxia
Hypoxia induces a number of complex intracellular signaling
pathways such as the major hypoxia-inducible factor (HIF)
pathway. Other hypoxia-associated pathways include PI3K/
AKT/mTOR,29,30 MAPK also known as ERK pathways,31–33
and the NFĸB.34 These pathways are involved in cell proliferation, survival, apoptosis, metabolism, migration, and
inflammation.
PI3K/AKT/mTOR, MAPK, and NFĸB signaling pathways are also stimulated in a hypoxia-independent manner
by a number of factors such as cytokines, chemokines, and
growth factors which bind to receptor tyrosine kinases,
G protein-coupled receptors, toll-like receptors (TLR), and
alarmins receptors on the cell surface, which eventually
may also lead to HIF-1α activation (Figure 1). In addition,
in cancer cells epigenetic changes and acquired mutations
of the pathways’ members and overactivation/overstimulation of receptors cause uncontrollable cancer cell growth.35
Targeting non-HIF pathways provides a promising target for
anti-neoplastic therapy and each pathway is a vast topic on
its own. More information regarding the role of the non-HIF
pathways in cancer can be found elsewhere. This review will
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Figure 1 Regulation of HIF in normoxic and hypoxic conditions.
Notes: HIF-α, a transcription factor, can be regulated by both hypoxic and non-hypoxic factors. In normoxia, HIF-α subunits are hydroxylated by oxygen sensors, including
PHD and FIH-1 enzymes, causing polyubiquitination and proteasomal degradation of hydroxylated HIF-α subunits (red arrows). PHD and FIH-1’s activity is oxygen-dependent
(red arrows); in hypoxia (blue arrows) these enzymes lose their activity due to decreased oxygenation, resulting in HIF-α protein stabilization, accumulation, and translocation
into the nucleus resulting in gene transcription and biological consequences (black arrows). HIF is also modulated in a hypoxia-independent manner in response to nitric oxide
(NO), reactive oxygen species (ROS), cytokines, lipopolysaccharides, and growth factors through receptor tyrosine kinases (RTK), G protein-coupled receptors (GPCRs),
toll-like receptors (TLR) and alarmins receptors. The non-hypoxic HIF regulation is mediated by a number of different signaling pathways including NFκB, PI3K/AKT/mTOR,
and MAPK/ERK (green arrows). These pathways, as well as ROS production, are additionally regulated by hypoxia, which results in multiple levels of HIF-α stimulation, both
hypoxic and normoxic. As a result, HIF accumulation and activation alters blood vessel formation, apoptosis, metastasis, and metabolism via a number of genes including
VEGF, SDF-1, Ang-2, MMPs, BNIP-3, p53, epithelial-to-mesenchymal transition (EMT), E-cad, CXCR4, LOX, CAIX, GLUT-1, and GSK (black arrows).

mainly concentrate on the HIF pathway and its involvement
in tumor progression.

HIF pathway
Cellular adaptation to hypoxia is primarily mediated by a
family of transcriptional regulators, HIF, which was identified
2 decades ago.36 The hypoxic induction and protein stabilization of HIF-α subunits (HIF-1α, HIF-2α, and HIF-3α)
is regulated by oxygen sensors, including PHD and FIH-1
enzymes. PHDs and FIH-1 are upstream of HIF-α and their
activity is oxygen-dependent.37 In oxygenated cells, HIF-α
subunits are hydroxylated by PHDs and FIH-1, which facilitate the tagging of HIF-α-OH by pVHL, polyubiquitination
and protein degradation of HIF-α by the proteasome.38
When the oxygen level drops, the PHD enzymes lose their
activity, the hydroxylation of the HIF-α subunit is inhibited and the degradation halted. The non-hydroxylated,
stabilized HIF-α subunits translocate to the nucleus where
they dimerize with constitutively expressed HIF-β subunit,

Hypoxia 2015:3

bind to DNA and initiate gene transcription of the adaptive
pathways (Figure 1).37
Apart from hypoxia, the HIF pathway is modulated in a
hypoxia-independent manner. HIF-α stabilization and activity is regulated by epigenetic changes and mutations, which
lead to a loss of tumor-suppressor functions (ING4, p53,
PTEN, VHL) and a gain of oncogene functions (Ras, Raf, Src,
mTOR, and Myc).39–41 Hypoxia-independent HIF-α regulation occurs in response to cytokines, lipopolysaccharides, and
growth factors, mediated by PI3K/AKT/mTOR,29,30 MAPK,41
and NFĸB pathways.42,43 In addition, mitochondrial ROS44,45
and nitric oxide (NO)46 were shown to up- or downregulate
HIF-1α accumulation (Figure 1).
Due to the diversified character of tumors including
hypoxic and inflammatory phenotype, signaling pathways
are activated simultaneously and they frequently share a
number of target genes. HIF-1α and NFĸB together regulate
over 1,000 genes, and thus control malignant and metastatic
phenotype of cancer cells since they both: i) enhance cell
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survival via a number of growth factors and inhibition of proapoptotic pathways, ii) contribute to tumor neovascularization
via VEGF, VEGF receptors, COX-2, iNOS, iii) regulate cell
detachment via downregulation of adhesion molecules such as
cadherins, and iv) induce cell migration and invasion through
matrix degrading enzymes.43 The HIF and NFKB pathways are
controlled by a negative feedback loop mechanism and also
intersect via alarmins. Tissue damage and necrosis, which can
be also induced by hypoxia, increases the presence of alarmins, the endogenous markers for damage, which are recognized
by receptor for advanced glycation endproducts (RAGE) and
some of TLRs. In addition, the expression of RAGE receptor is also upregulated by HIF-1a. In turn, alarmin receptors
strongly activate NFkB and proinflammatory gene expression.
Moreover, the basal HIF-1a mRNA expression is regulated by
NFKB in non-hypoxic conditions since HIF-1a promoter was
shown to be responsive to certain NFKB subunits.39
The HIF pathway is required during physiological
processes and is implicated in cancer biology by regulating hundreds of genes.47–49 This master regulator facilitates
tumor growth by promoting angiogenesis via VEGF and
SDF-1,50,51 metabolism via regulation of GLUT-1, GLUT-3,
and glycolytic enzymes,52–54 and regulating cell apoptosis
and cell survival via BNIP-3,55 p53,56,57 TGF-β, and bFGF.3
Moreover, HIF-α contributes to cancer metastasis by altering cancer cell adhesion and motility through regulation
of epithelial-to-mesenchymal transition (EMT) and E-cad,
ZEB1, -2 and TCF3 expression,58 as well as migration and
invasion abilities through CXCR4,59 CAIX,60 LOX,61 MMP-2,
and MMP-9.47,62,63

The role of hypoxia in progression
and metastasis in cancer
Pathological hypoxia is a common microenvironment factor
in tumors that facilitates cell survival and propagation of
the tumor. Key cellular responses to hypoxia triggered by
overexpression of HIF-1α and HIF-2α subunits and their
downstream targets increase blood vessel formation, aggressiveness, metastasis, and resistance to treatment.

Blood vessel formation
Blood vessels create a network of tubes and capillaries which
nourish the entire body with oxygen and nutrients. Thus, the
way they are formed and function is crucial in embryogenesis and physiology. Blood vessels consists of endothelial
cells (ECs) which create a tight barrier between the blood
and tissue, and interact with ECM. In embryogenesis, blood
vessels are formed de novo by vasculogenesis involving

86

submit your manuscript | www.dovepress.com

Dovepress

bone marrow-derived endothelial progenitor cells (EPCs)64
followed by angiogenesis, a process where new blood vessels
are created from pre-existing vasculature.65 Lastly, the vessels
undergo maturation which includes physical interaction with
smooth muscle cells and pericytes. Abnormal angiogenesis
is a feature of pathological conditions including tumor
progression, where hyperproliferating cancer cells surpass
their blood supply and become hypoxic. Hypoxia induces the
imbalance between pro- and anti-angiogenic factors’ production, which leads to enhanced, rapid and chaotic blood vessel
formation. Hypoxia and potent transcription factors HIF-1α
and HIF-2α have been shown to be involved in all steps of
blood vessel formation.36,64,65 i) Hypoxia and HIF-α subunits
contribute to the EPCs’ recruitment from the bone marrow
and induction of their differentiation into ECs by regulation
of VEGF, a primary regulator of vasculogenesis. This is also
mediated through stimulation of pro-angiogenic molecule
production such as VEGF-R2 (Flk-1), members of the FGF
family and PDGF, important in the primitive vascular network
formation.64,66 ii) Hypoxia and HIF-α are also involved in the
angiogenesis process by inducing enzymes’ expression (ie,
MMPs) in order to sprout and split the pre-existing vessels.
In turn, neovessels allows ECs to migrate in response to
chemoattractants across ECM. Additionally hypoxia induces
ECs’ proliferation by regulation of VEGF-R1 (Flt-1), Ang-1
and Ang-2 expression.67 iii) Finally, hypoxia and HIF-α support vessel maturation via induction of Ang-1, PDGF, and
TGF-β to recruit supporting cells such as smooth muscle cells
and pericytes creating mature and stable blood vessels.67
However, in tumors, neovessels are often abnormal,
immature, and leaky. They are either insufficient or excessive
depending on the tumor type.65 Neovasculogenesis maintains
blood flow to the growing tumor tissue that expands rapidly,
providing nutrients and oxygen for thriving cancer cells;
however, more cells means more demand causing even more
hypoxia. Again, hypoxia in turn stimulates angiogenesis to
ameliorate hypoxic condition, closing the vicious circle. As
a consequence the tumor tissue ends up being highly hypoxic
with excessive but dysfunctional vasculature.68
Folkman was the first to propose anti-angiogenic therapy
to treat cancer in 1971.69 A successful use of monoclonal antibody against VEGF (bevacizumab) approved for treatment
of metastatic colorectal cancer70 followed by multiple solid
tumors, has stimulated development of other anti-angiogenic
therapies. However, long-term exposure to these agents
revealed not only reducing tumor growth, but also more
malignant and invasive cancer phenotype increasing metastasis.71 Long-term exposure to anti-angiogenic agents reduce
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tumor; however, at the same time induce more aggresive and
metastatic tumor phenotype.71,72

Metastasis
Enhanced angiogenesis is associated with metastasis since
permeable and heterogeneous vasculature facilitates the
extravasation, circulation, and relocation of tumor cells of
tumor cells to new and unaffected tissues escaping the hostile
hypoxic environment.68 Tumor oxygenation is a critical factor of cancer progression and the overexpression of HIF-α
subunits in tumors and their metastases is associated with the
aggressiveness of a majority of human cancers and correlates
with poor overall survival.49,73,74
It was demonstrated previously that hypoxic cells are
more aggressive and invasive with better ability to metastasize. For instance, multiple myeloma cancer cells cultured in
hypoxic conditions in vitro and injected into mice were able to
spread to the new bone marrow faster than the cells cultured
in normoxic conditions.63,75 Also, exposing an orthotopic
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Figure 2 Hypoxia as a driving force of tumor progression and metastasis.
Notes: Hypoxia stimulates tumor i) vasculogenesis through endothelial progenitor
cells’ mobilization from the bone marrow to the tumor site by VEGF, VEGF-R2,
fibroblast growth factor (FGF), platelet-derived growth factor (PDGF) and stromalderived growth factor-1 (SDF-1) and ii) angiogenesis by sprouting of the pre-existing
vessels caused by increased production of VEGF, VEGF-R1, VEGF-R2, Ang-1, Ang-2,
and MMPs. New blood vessels facilitate cancer cells leaving the primary tumor site,
which is enhanced by increased expression of lysyl oxidase (LOX), carbonic anhydrase
IX (CAIX), MMPs, integrins, and CXCR4. Hypoxic cancer cells also undergo
epithelial-to-mesenchymal transition (EMT) acquiring plastic and mobile phenotype
by increasing transcription factors such as Slug, Snail, and Twist and decreasing
expression of adhesion molecules such as β-catenin and E-cadherin (E-cad). Chemoand radio-resistance of patients is caused by EMT-related stemness of cancer cells
and hypoxia-induced cell cycle arrest in G1 phase. Hindered drug diffusion due to
anomalous vascularity is another mechanism of chemoresistance.
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mouse model of cervical carcinoma to a dozen cycles of 10
minutes 7% O2, which was followed by 10 minutes of air
exposure daily, increased the number of lymph node metastases.76 Similar observations were recorded in mice bearing
sarcoma tumors, where exposure to acute hypoxia augmented
the lung metastases.77
Mechanistically, hypoxia was shown to influence
invasive and migratory behavior of cancer cells via EMT,
a trans-differentiation of cells in order to acquire plastic and
mobile abilities, a process which alters their gene expression
prior to migration.78 EMT is physiologically active during
embryogenesis and tissue regeneration, as well as in cancerogenesis in many types of solid tumors79 and hematologic
malignancies.63 Hypoxia-induced EMT is characterized by
a decrease in epithelial-associated gene expression, such
as E-cad, β-catenin80 and an increase in mesenchymal-like
gene expression, such as N-cad,81 vimentin, SMA,82 and
CXCR4.63,75 EMT is promoted by a master regulator TGF-β,
also increased by hypoxia, which activates downstream
transcription factors such as Smads, Snail, Slug, and Twist,
and inhibits expression of E-cad.63,83 Interestingly, radio- and
chemoresistance was also shown to be associated with EMT
phenotype; expression of Snail and Slug antagonizes p53mediated apoptosis and promotes resistance to radiation and
chemotherapeutic agents such as paclitaxel and cisplatin in
ovarian cancer cells.84
Moreover, HIF-1α was shown to be expressed in 90%
of human gastric cancer biopsies at the front edge of the
invading tumor compared to HIF-1α negative normal tissues.74 HIF inhibition significantly reduced the metastasis of
gastric cancer cells in vivo, and HIF deficient cells were less
motile, invasive, and adhesive in vitro.74 High involvement of
the main hypoxic regulator, HIF-α, in all steps of metastasis
led to many trials of inhibiting this molecule to diminish
cancer cell trafficking thus reducing metastasis. Inhibition of
HIF-1 activity using antisense oligonucleotide (EZN-2968)
gave effective results and a safe toxicity in a Phase I clinical
trial in metastatic, advanced solid malignancy.85 Targeting
hypoxic cells with a pro-drug, activated only in a hypoxic
environment, is one of the newest and highly promising
strategies to reduce metastasis, currently undergoing phase
I/II clinical trials in multiple myeloma, a model of a process
of metastasis.86
Apart from targeting HIF-α molecules, another strategy
to inhibit metastasis is to target genes downstream of HIF-α.
For instance, CAIX is a hypoxia-inducible enzyme widely
present in tumors; it is crucial in regulating intra- and extracellular pH, thus CAIX promotes survival and invasion of
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cancer cells.87 It was demonstrated that, inhibition of CAIX
decreased tumor growth and metastasis in pre-clinical breast
tumor models.87 LOX is another protein elevated in hypoxic
human tumor cells (such as breast, and head and neck cancer)
and is HIF-α-dependent.61 LOX secreted by tumor cells
accumulates at new sites and mediates bone marrow-derived
cell recruitment which forms a “pre-metastatic niche” for
future metastasis.88 Inhibition of LOX reduced hypoxiainduced recruitment and metastasis in the breast cancer
mouse model.88 Another target candidate induced by hypoxia
in cancer cells is CXCR4 involved in cell trafficking.89,90 It
was demonstrated that metastatic tumor cells expressing high
levels of CXCR4 home to tissues rich in its ligand, SDF-1,63,91
and inhibitors of CXCR4/SDF-1 axis resulted in disruption
of the metastatic process (Figure 2).90

Radiation and drug resistance
Resistance of cancer cells to treatment-induced apoptosis is
one of the biggest obstacles in cancer therapy.92 A vast number
of cancer patients relapse and suffer from recurring tumors as
a result of micro-residual disease, the resistant subpopulation
of cancer cells, leading to local recurrence and/or metastasis.93
Tumor hypoxia develops due to uncontrollable cell proliferation, altered metabolism, and abnormal tumor blood vessels
resulting in reduced transport of oxygen and nutrients.13
Hypoxia is one of the main features of solid tumors and was
shown to correlate with poor prognosis of cancer patients.73
While hypoxia is lethal for many cells, a subpopulation of
tumor cells is able to not only adapt to hypoxic conditions
but also become resistant to chemo- and radiotherapy. The
role of hypoxia in the phenomenon of therapy resistance has
been acknowledged for at least 60 years.94,95
Hypoxia confers treatment resistance of cancer cells by
regulating processes such as i) inducing cell cycle arrest
(quiescence), a state of reduced cell proliferation which protects the cells from external stress,96,97 ii) inhibiting apoptosis
and senescence of cells, iii) controlling autophagy, p53, and
mitochondrial activity.94,97 Apart from cellular adaptations
influenced by hypoxia, lowered oxygenation of the tumor
tissue confers chemoresistance by affecting iv) drug delivery and cellular uptake through associated acidity and drug
efflux pump expression such as P-gp,98 as well as by the
v) lack of oxygen required for the cytotoxicity of a number
of chemotherapeutics.99
One of the most important parameters of radio-resistance
is oxygenation, the state of cell cycle, and the nature of
radiation, whether it is gamma, X-ray, neutron radiation, or
linear energy transfer including alpha and beta particles.94,96
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When oxygen is abundant, the normoxic cells are sensitive
to radiation, due to “oxygen fixation” which happens when
available molecules of oxygen react with free radicals in
DNA generated by ionizing radiation leading to irreversible
DNA damage. Whereas, cells irradiated in hypoxic conditions are resistant to death, due to decreased production of
DNA radicals (which can be restored “chemical restitution”)
caused by reduced generation of ROS and decreased DNA
damage.95 The cell cycle phase determines the radiosensitivity
of the tumors. It was shown that cells exposed to ionizing
radiation are the least sensitive at the end of S phase, less
sensitive in the G1 phase, and the most radiosensitive in the
G2/M phase where DNA repair mechanisms are the most
prone to malfunction.100 Hence, anticancer treatments, both
radio- and chemotherapy, preferentially target the bulk of
rapidly proliferating tumor cells. On the other hand, the
cells which are most resistant to treatment are quiescent,
low-proliferating, stem-cell-like cell fractions residing in
the most hypoxic region.82,84,97,101 For instance, it was demonstrated that glioblastoma cancer stem cells (CD133+) showed
higher DNA repair and decreased apoptosis in response
to irradiation, compared to non-stem-cell-like (CD133-)
population.94,96,102
Hypoxia causes slow-proliferating stem-cell-like phenotype of cells, decreases senescence, creates chaotic and malfunctioning blood vessels, and augments metastasis, which
all together further induces therapy resistance.96 Currently,
assessment of tumor oxygenation and HIF expression pattern
helps determine tumor chemo- and radio-sensitivity.94,103 It
was reported that head-and-neck cancer samples with high
expression of HIF-1α and HIF-2α were more resistant to
chemotherapy (carboplatin) compared to biopsies with low
HIF-α expression which were chemo-sensitive.104 Patients
with oropharyngeal cancer demonstrating high expression of HIF-1α had a lower chance to achieve complete
remission after irradiation.103 In addition, irradiation was
shown to induce HIF-1 activity, leading to production of
angiogenic molecules such as VEGF which protects ECs
from irradiation-induced apoptosis.105 Therefore HIF-1 represents a valid predictive marker and therapeutic target for
manipulation, in combination with chemotherapeutics and
radiotherapy, in order to sensitize the cells to treatments.73
As demonstrated by others, inactivation of HIF-1α in
mouse embryonic fibroblasts increased their susceptibility
to carboplatin and etoposide compared to wild-type, both
in vitro and in vivo.106 Similarly, inhibition of HIF-2α with
short hairpin RNA reversed the resistance to doxorubicin
and etoposide of human clear cell renal cell cancer cells
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(one of the most resistant tumors) by restoring p53.57 It
was reported that treating tumor-bearing mice with HIF-1
inhibitor (YC-1) induced radiation-induced vessel damage.105
Similarly, treatment of glioma, squamous and pancreatic
cancer cells with the HIF-1α inhibitor (PX-478) radiosensitized hypoxic cells.107 Silencing of HIF-1α with siRNA
in mouse embryonic fibroblasts increased susceptibility to
irradiation;106 and also, HIF-2α inhibition was shown to
enhance radiation-induced apoptosis due to HIF-2-mediated
increase of p53 activity and accumulation of ROS, thus DNA
damage (Figure 2).108

Tumor microenvironment
The tumor would not thrive without the interaction, crosstalk, and support with the tumor microenvironment including
cellular components such as stromal cells, immune cells, ECs
as well as non-cellular components including ECM, cyto
kines, and other mediators.109 Thus, in hypoxic tumor tissue,
not only cancer cells but also the tumor microenvironment
is affected by hypoxia-inducible changes.110
Hypoxia was shown to induce metabolic and molecular
changes in ECs, increasing expression of pro-angiogenic
molecules, blood vessel formation, and thus providing more
oxygen and nutrients for tumor cells. Hypoxia also regulates
inflammatory mediators and growth factors, which then
stimulate platelet, leukocyte, and smooth muscle cell activity.
One of the most significant changes is increase in adhesiveness of ECs to neutrophils facilitating NK cell trafficking and
local inflammatory reaction.111 Depending on the duration
of oxygen depletion, hypoxia regulates expression of NO
synthase expression contributing to vasoconstriction.112 Since
blood vessels nourish tumors, targeting ECs will prevent or
reverse tumor growth.110,113–115
Stromal cells, on the other hand, facilitate tumor growth
and tumor dissemination mostly by regulating cancer cell
adhesion and contributing to cell proliferation and survival.
It was shown that hypoxia induces stromal cells to produce
a number of factors including Ang-2, ANGPTL-4, PDGF,
VEGF, SDF-1, LOX, and SCF (KIT-ligand), influencing ECs
and EPCs thus promoting new blood vessel formation and
lymphangiogenesis. Also, stromal-derived SDF-1 attracts
cancer cells and thus facilitates metastasis.115,116
It was demonstrated that hypoxia leads to immuneresistance and immune-suppression, which help tumor
cells to escape from immune surveillance.117,118 Some of the
immune-suppressive effects include: 1) shedding of immunerecognition molecules by tumor hypoxia, which results
in decreased sensitivity to T- and NK-mediated killing;119
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2) inhibition of T cells’ and dendritic cells’ maturation and
cytokine production;120 3) and promotion of suppressive cells
such as regulatory T cells and tumor-associated macrophages,
which block immune effector cells.121
Therefore, there is an increasing importance of the
hypoxic phenotype of stromal and immune cells in the tumor
microenvironment providing non-cancer cells as potential
novel targets in the fight against the tumor.110

Conclusion
Pathological hypoxia affects both cancer cells and the
tumor microenvironment, and plays a pivotal role in the
process of cancer progression and dissemination. Hypoxia
regulates tumor neovascularization, metabolism, cell survival, and cell death. In addition, hypoxia contributes to
EMT-like cancer cell migration and cancer stem-cell-like
properties including resistance to treatment, one of the
nightmares in the medical field. Each step of the cancer
adaptive processes is controlled by hypoxia-activating
transcriptional programs involving HIF, NFĸB, PI3K, and
MAPK pathways.
Since hypoxia signifies increased tumor progression
and aggressiveness hampering patients’ survival, direct
and indirect methods of measuring hypoxia combined with
clinical observations may help to predict patients’ outcome
as well as identify patients who could benefit from hypoxia/
HIF-targeted treatments. Better understanding of hypoxic
phenomenon and dissecting out the hypoxia-inducible
responses and signaling pathways will grant numerous novel
targets in the near future.

Disclosure
Dr AK Azab receives research support from Verastem, Selexys, Karyopharm and Cell Works, and is the founder and
owner of Targeted Therapeutics LLC and Cellatrix LLC. No
potential conflicts of interest were disclosed by B Muz, P de
la Puente and F Azab.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global
cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
2. Thomlinson RH, Gray LH. The histological structure of some human
lung cancers and the possible implications for radiotherapy. Br J Cancer.
1955;9(4):539–549.
3. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor
progression. Crit Rev Biochem Mol Biol. 2000;35(2):71–103.
4. Hockel M, Schlenger K, Knoop C, Vaupel P. Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension
measurements. Cancer Res. 1991;51(22):6098–6102.
5. Carreau A, El Hafny-Rahbi B, Matejuk A, Grillon C, Kieda C. Why is
the partial oxygen pressure of human tissues a crucial parameter? Small
molecules and hypoxia. J Cell Mol Med. 2011;15(6):1239–1253.

submit your manuscript | www.dovepress.com

Dovepress

89

Dovepress

Muz et al
6. Vaupel P, Hockel M, Mayer A. Detection and characterization of
tumor hypoxia using pO2 histography. Antiox Redox Signal. 2007;
9(8):1221–1235.
7. Muller M, Padberg W, Schindler E, et al. Renocortical tissue oxygen
pressure measurements in patients undergoing living donor kidney
transplantation. Anesth Analg. 1998;87(2):474–476.
8. Dings J, Meixensberger J, Jager A, Roosen K. Clinical experience with
118 brain tissue oxygen partial pressure catheter probes. Neurosurgery.
1998;43(5):1082–1095.
9. Hoffman WE, Charbel FT, Edelman G. Brain tissue oxygen, carbon
dioxide, and pH in neurosurgical patients at risk for ischemia. Anesth
Analg. 1996;82(3):582–586.
10. Cervos-Navarro J, Diemer NH. Selective vulnerability in brain hypoxia.
Crit Rev Neurobiol. 1991;6(3):149–182.
11. Wenger RH, Kurtcuoglu V, Scholz CC, Marti HH, Hoogewijs D.
Frequently asked questions in hypoxia research. Hypoxia. 2015(3):
35–43.
12. Bayer C, Vaupel P. Acute versus chronic hypoxia in tumors: Controversial
data concerning time frames and biological consequences. Strahlenther
Onkol. 2012;188(7):616–627.
13. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory
mechanisms, and cellular response. Oncologist. 2004;9 Suppl 5:4–9.
14. Chaplin DJ, Olive PL, Durand RE. Intermittent blood flow in a murine
tumor: radiobiological effects. Cancer Res. 1987;47(2):597–601.
15. Mazure NM, Pouyssegur J. Hypoxia-induced autophagy: cell death or
cell survival? Curr Opin Cell Biol. 2010;22(2):177–180.
16. Rouschop KM, Ramaekers CH, Schaaf MB, et al. Autophagy is required
during cycling hypoxia to lower production of reactive oxygen species.
Radiother Oncol. 2009;92(3):411–416.
17. Hsieh CH, Lee CH, Liang JA, Yu CY, Shyu WC. Cycling hypoxia
increases U87 glioma cell radioresistance via ROS induced higher
and long-term HIF-1 signal transduction activity. Oncol Rep. 2010;
24(6):1629–1636.
18. Hsieh CH, Shyu WC, Chiang CY, Kuo JW, Shen WC, Liu RS.
NADPH oxidase subunit 4-mediated reactive oxygen species contribute to cycling hypoxia-promoted tumor progression in glioblastoma
multiforme. PloS One. 2011;6(9):e23945.
19. Kato Y, Yashiro M, Fuyuhiro Y, et al. Effects of acute and chronic
hypoxia on the radiosensitivity of gastric and esophageal cancer cells.
Anticancer Res. 2011;31(10):3369–3375.
20. Chaplin DJ, Durand RE, Olive PL. Acute hypoxia in tumors: implications
for modifiers of radiation effects. Int J Radiat Oncol Biol Phys.
1986;12(8):1279–1282.
21. Bellot G, Garcia-Medina R, Gounon P, et al. Hypoxia-induced
autophagy is mediated through hypoxia-inducible factor induction
of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol. 2009;
29(10):2570–2581.
22. Rofstad EK, Gaustad JV, Egeland TA, Mathiesen B, Galappathi K.
Tumors exposed to acute cyclic hypoxic stress show enhanced
angiogenesis, perfusion and metastatic dissemination. Int J Cancer.
2010;127(7):1535–1546.
23. Chan N, Koritzinsky M, Zhao H, et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance
and radioresistance. Cancer Res. 2008;68(2):605–614.
24. Luoto KR, Kumareswaran R, Bristow RG. Tumor hypoxia as a driving
force in genetic instability. Genome Integr. 2013;4(1):5.
25. Kondo A, Safaei R, Mishima M, Niedner H, Lin X, Howell SB.
Hypoxia-induced enrichment and mutagenesis of cells that have lost
DNA mismatch repair. Cancer Res. 2001;61(20):7603–7607.
26. Pires IM, Bencokova Z, Milani M, et al. Effects of acute versus chronic
hypoxia on DNA damage responses and genomic instability. Cancer
Res. 2010;70(3):925–935.
27. Brurberg KG, Graff BA, Olsen DR, Rofstad EK. Tumor-line specific
pO(2) fluctuations in human melanoma xenografts. Int J Radiat Oncol
Biol Phys. 2004;58(2):403–409.
28. Kimura H, Braun RD, Ong ET, et al. Fluctuations in red cell flux in
tumor microvessels can lead to transient hypoxia and reoxygenation in
tumor parenchyma. Cancer Res. 1996;56(23):5522–5528.

90

submit your manuscript | www.dovepress.com

Dovepress

29. Agani F, Jiang BH. Oxygen-independent regulation of HIF-1: novel
involvement of PI3K/AKT/mTOR pathway in cancer. Curr Cancer
Drug Targets. 2013;13(3):245–251.
30. Courtnay R, Ngo DC, Malik N, Ververis K, Tortorella SM, Karagiannis TC.
Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K.
Mol Biol Rep. 2015;42(4):841–851.
31. Seta KA, Spicer Z, Yuan Y, Lu G, Millhorn DE. Responding to hypoxia:
lessons from a model cell line. Sci STKE. 2002;2002(146):re11.
32. Sanchez A, Tripathy D, Yin X, et al. p38 MAPK: a mediator of
hypoxia-induced cerebrovascular inflammation. J Alzheimers Dis.
2012;32(3):587–597.
33. Minet E, Arnould T, Michel G, et al. ERK activation upon hypoxia:
involvement in HIF-1 activation. FEBS Lett. 2000;468(1):53–58.
34. Koong AC, Chen EY, Giaccia AJ. Hypoxia causes the activation of
nuclear factor kappa B through the phosphorylation of I kappa B alpha
on tyrosine residues. Cancer Res. 1994;54(6):1425–1430.
35. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor
suppression. Cell. 2008;133(3):403–414.
36. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de
novo protein synthesis binds to the human erythropoietin gene enhancer
at a site required for transcriptional activation. Mol Cell Biol. 1992;
12(12):5447–5454.
37. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases
that modify HIF. Science. 2001;294(5545):1337–1340.
38. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor
protein VHL targets hypoxia-inducible factors for oxygen-dependent
proteolysis. Nature. 1999;399(6733):271–275.
39. van Uden P, Kenneth NS, Rocha S. Regulation of hypoxia-inducible
factor-1alpha by NF-kappaB. Biochem J. 2008;412(3):477–484.
40. Kilic-Eren M, Boylu T, Tabor V. Targeting PI3K/Akt represses Hypoxia
inducible factor-1alpha activation and sensitizes Rhabdomyosarcoma
and Ewing’s sarcoma cells for apoptosis. Cancer Cell Int. 2013;13:36.
41. Richard DE, Berra E, Gothie E, Roux D, Pouyssegur J. p42/p44
mitogen-activated protein kinases phosphorylate hypoxia-inducible
factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of
HIF-1. J Biol Chem. 1999;274(46):32631–32637.
42. Royds JA, Dower SK, Qwarnstrom EE, Lewis CE. Response of tumour
cells to hypoxia: role of p53 and NFkB. Mol Pathol. 1998;51(2):55–61.
43. Tafani M, Pucci B, Russo A, et al. Modulators of HIF1alpha and
NFkB in Cancer Treatment: Is it a Rational Approach for Controlling
Malignant Progression? Front Pharmacol. 2013;4:13.
44. Chandel NS, McClintock DS, Feliciano CE, et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible
factor-1alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem.
2000;275(33):25130–25138.
45. Movafagh S, Crook S, Vo K. Regulation of hypoxia-inducible factor-1a
by reactive oxygen species: new developments in an old debate. J Cell
Biochem. 2015;116(5):696–703.
46. Mateo J, Garcia-Lecea M, Cadenas S, Hernandez C, Moncada S.
Regulation of hypoxia-inducible factor-1alpha by nitric oxide through
mitochondria-dependent and -independent pathways. Biochem J.
2003;376(Pt 2):537–544.
47. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci.
2012;33(4):207–214.
48. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on
human cancer. Nat Rev Cancer. 2008;8(12):967–975.
49. Muz B, de la Puente P, Azab F, Luderer M, Azab AK. The role of
hypoxia and exploitation of the hypoxic environment in hematologic
malignancies. Mol Cancer Res. 2014;12(10):1347–1354.
50. Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G,
Marme D. Reversion of deregulated expression of vascular endothelial
growth factor in human renal carcinoma cells by von Hippel-Lindau
tumor suppressor protein. Cancer Res. 1996;56(10):2299–2301.
51. Zagzag D, Krishnamachary B, Yee H, et al. Stromal cell-derived factor1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal
cell carcinoma: von Hippel-Lindau loss-of-function induces expression
of a ligand and its receptor. Cancer Res. 2005;65(14):6178–6188.
Hypoxia 2015:3

Dovepress
52. Iyer NV, Kotch LE, Agani F, et al. Cellular and developmental control
of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev.
1998;12(2):149–162.
53. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA. Negative
regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
Proc Natl Acad Sci U S A. 1996;93(20):10595–10599.
54. Semenza GL. HIF-1 mediates metabolic responses to intratumoral
hypoxia and oncogenic mutations. J Clin Invest. 2013;123(9):
3664–3671.
55. Guo K, Searfoss G, Krolikowski D, et al. Hypoxia induces the expression of the pro-apoptotic gene BNIP3. Cell Death Differ. 2001;8(4):
367–376.
56. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV,
Neckers LM. Stabilization of wild-type p53 by hypoxia-inducible factor 1
alpha. Nature. 1998;392(6674):405–408.
57. Roberts AM, Watson IR, Evans AJ, Foster DA, Irwin MS, Ohh M.
Suppression of hypoxia-inducible factor 2alpha restores p53 activity via
Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer
Res. 2009;69(23):9056–9064.
58. Krishnamachary B, Zagzag D, Nagasawa H, et al. Hypoxia-inducible
factor-1-dependent repression of E-cadherin in von Hippel-Lindau
tumor suppressor-null renal cell carcinoma mediated by TCF3,
ZFHX1A, and ZFHX1B. Cancer Res. 2006;66(5):2725–2731.
59. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W.
Chemokine receptor CXCR4 downregulated by von Hippel-Lindau
tumour suppressor pVHL. Nature. 2003;425(6955):307–311.
60. Grabmaier K, MC AdW, Verhaegh GW, Schalken JA, Oosterwijk E.
Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal
cell carcinoma. Oncogene. 2004;23(33):5624–5631.
61. Erler JT, Bennewith KL, Nicolau M, et al. Lysyl oxidase is
essential for hypoxia-induced metastasis. Nature. 2006;440(7088):
1222–1226.
62. Krishnamachary B, Berg-Dixon S, Kelly B, et al. Regulation of colon
carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res.
2003;63(5):1138–1143.
63. Azab AK, Hu J, Quang P, et al. Hypoxia promotes dissemination of
multiple myeloma through acquisition of epithelial to mesenchymal
transition-like features. Blood. 2012;119(24):5782–5794.
64. Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood
vessel growth. Cardiovasc Res. 2001;49(3):507–521.
65. Carmeliet P. Angiogenesis in life, disease and medicine. Nature.
2005;438(7070):932–936.
66. de la Puente P, Muz B, Azab F, Azab AK. Cell Trafficking of Endothelial Progenitor Cells in Tumor Progression. Clin Cancer Res. 2013;
19(3):3360–3368.
67. Krock BL, Skuli N, Simon MC. Hypoxia-induced angiogenesis: good
and evil. Genes Cancer. 2011;2(12):1117–1133.
68. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications
of angiogenesis. Nature. 2011;473(7347):298–307.
69. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J
Med. 1971;285(21):1182–1186.
70. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
N Engl J Med. 2004;350(23):2335–2342.
71. Mountzios G, Pentheroudakis G, Carmeliet P. Bevacizumab and
micrometastases: revisiting the preclinical and clinical rollercoaster.
Pharmacol Ther. 2014;141(2):117–124.
72. Jain RK. Normalization of tumor vasculature: an emerging concept in
antiangiogenic therapy. Science. 2005;307(5706):58–62.
73. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer
biology and therapeutics. Oncogene. 2010;29(5):625–634.
74. Rohwer N, Lobitz S, Daskalow K, et al. HIF-1alpha determines
the metastatic potential of gastric cancer cells. Br J Cancer. 2009;
100(5):772–781.
75. Muz B, de la Puente P, Azab F, Ghobrial IM, Azab AK. Hypoxia
promotes dissemination and colonization in new bone marrow niches
in Waldenstrom macroglobulinemia. Mol Cancer Res. 2015;13(2):
263–272.
Hypoxia 2015:3

The role of hypoxia in cancer
76. Cairns RA, Hill RP. Acute hypoxia enhances spontaneous lymph node
metastasis in an orthotopic murine model of human cervical carcinoma.
Cancer Res. 2004;64(6):2054–2061.
77. Cairns RA, Kalliomaki T, Hill RP. Acute (cyclic) hypoxia enhances
spontaneous metastasis of KHT murine tumors. Cancer Res.
2001;61(24):8903–8908.
78. Thiery JP, Sleeman JP. Complex networks orchestrate epithelialmesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131–142.
79. Mulholland DJ, Kobayashi N, Ruscetti M, et al. Pten loss and
RAS/MAPK activation cooperate to promote EMT and metastasis
initiated from prostate cancer stem/progenitor cells. Cancer Res.
2012;72(7):1878–1889.
80. Kim K, Lu Z, Hay ED. Direct evidence for a role of beta-catenin/
LEF-1 signaling pathway in induction of EMT. Cell Biol Int. 2002;
26(5):463–476.
81. Hsu M, Andl T, Li G, Meinkoth JL, Herlyn M. Cadherin repertoire
determines partner-specific gap junctional communication during
melanoma progression. J Cell Sci. 2000;113(Pt 9):1535–1542.
82. Manotham K, Tanaka T, Matsumoto M, et al. Transdifferentiation
of cultured tubular cells induced by hypoxia. Kidney Int. 2004;65(3):
871–880.
83. Tian M, Neil JR, Schiemann WP. Transforming growth factor-beta and
the hallmarks of cancer. Cell Signal. 2011;23(6):951–962.
84. Tamara Marie-Egyptienne D, Lohse I, Hill RP. Cancer stem cells,
the epithelial to mesenchymal transition (EMT) and radioresistance:
Potential role of hypoxia. Cancer Lett. 2013;341(1):63–72.
85. Greenberger LM, Horak ID, Filpula D, et al. A RNA antagonist of
hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth.
Mol Cancer Ther. 2008;7(11):3598–3608.
86. Hu J, Handisides DR, Van Valckenborgh E, et al. Targeting the multiple
myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.
Blood. 2010;116(9):1524–1527.
87. Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia:
suppression of breast tumor growth and metastasis by novel carbonic
anhydrase IX inhibitors. Cancer Res. 2011;71(9):3364–3376.
88. Erler JT, Bennewith KL, Cox TR, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the
premetastatic niche. Cancer Cell. 2009;15(1):35–44.
89. Azab AK, Azab F, Blotta S, et al. RhoA and Rac1 GTPases play
major and differential roles in stromal cell-derived factor-1-induced
cell adhesion and chemotaxis in multiple myeloma. Blood. 2009;
114(3):619–629.
90. Azab AK, Runnels JM, Pitsillides C, et al. CXCR4 inhibitor AMD3100
disrupts the interaction of multiple myeloma cells with the bone marrow
microenvironment and enhances their sensitivity to therapy. Blood.
2009;113(18):4341–4351.
91. Azab AK, Weisberg E, Sahin E, et al. The influence of hypoxia on CML
trafficking through modulation of CXCR4 and E-cadherin expression.
Leukemia. 2013;27(4):961–964.
92. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev
Cancer. 2011;11(6):393–410.
93. Munshi NC, Anderson KC. Minimal residual disease in multiple
myeloma. J Clin Oncol. 2013;31(20):2523–2526.
94. Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights
on the functional interaction of HIFs and cell death pathways. Drug
Resist Updat. 2011;14(3):191–201.
95. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor
in radiotherapy. Br J Radiol. 1953;26(312):638–648.
96. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors:
pathogenesis of hypoxia and significance for tumor therapy. Semin
Oncol. 2001;28(2 Suppl 8):29–35.
97. Das B, Tsuchida R, Malkin D, Koren G, Baruchel S, Yeger H. Hypoxia
enhances tumor stemness by increasing the invasive and tumorigenic
side population fraction. Stem Cells. 2008;26(7):1818–1830.
98. Abraham J, Salama NN, Azab AK. The role of P-glycoprotein in
drug resistance in multiple myeloma. Leuk Lymphoma. 2015;56(1):
26–33.
submit your manuscript | www.dovepress.com

Dovepress

91

Dovepress

Muz et al
99. Cosse JP, Michiels C. Tumour hypoxia affects the responsiveness
of cancer cells to chemotherapy and promotes cancer progression.
Anticancer Agents Med Chem. 2008;8(7):790–797.
100. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity
to radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(4):928–942.
101. Muz B, de la Puente P, Azab F, Luderer M, Azab AK. Hypoxia promotes
stem cell-like phenotype in multiple myeloma cells. Blood Cancer J.
2014;4:e262.
102. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote
radioresistance by preferential activation of the DNA damage response.
Nature. 2006;444(7120):756–760.
103. Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxiainducible factor-1alpha: a novel predictive and prognostic parameter
in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001;
61(7):2911–2916.
104. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-inducible
factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy
outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol
Biol Phys. 2002;53(5):1192–1202.
105. Moeller BJ, Cao Y, Vujaskovic Z, Li CY, Haroon ZA, Dewhirst MW.
The relationship between hypoxia and angiogenesis. Semin Radiat
Oncol. 2004;14(3):215–221.
106. Unruh A, Ressel A, Mohamed HG, et al. The hypoxia-inducible
factor-1 alpha is a negative factor for tumor therapy. Oncogene. 2003;
22(21):3213–3220.
107. Schwartz DL, Powis G, Thitai-Kumar A, et al. The selective hypoxia
inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther. 2009;
8(4):947–958.
108. Bertout JA, Majmundar AJ, Gordan JD, et al. HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation
responses. Proc Natl Acad Sci U S A. 2009;106(34):14391–14396.
109. Sounni NE, Noel A. Targeting the tumor microenvironment for cancer
therapy. Clin Chem. 2013;59(1):85–93.
110. Casazza A, Di Conza G, Wenes M, Finisguerra V, Deschoemaeker S,
Mazzone M. Tumor stroma: a complexity dictated by the hypoxic
tumor microenvironment. Oncogene. 2014;33(14):1743–1754.
111. Baudry N, Danialou G, Boczkowski J, Vicaut E. In vivo study of the
effect of systemic hypoxia on leukocyte-endothelium interactions. Am
J Respir Crit Care Med. 1998;158(2):477–483.
112. Kourembanas S, Bernfield M. Hypoxia and endothelial-smooth
muscle cell interactions in the lung. Am J Respir Crit Care Med. 1994;
11(4):373–374.
113. Michiels C, Arnould T, Remacle J. Endothelial cell responses to
hypoxia: initiation of a cascade of cellular interactions. Biochim
Biophys Acta. 2000;1497(1):1–10.
114. Verdegem D, Moens S, Stapor P, Carmeliet P. Endothelial cell metabolism: parallels and divergences with cancer cell metabolism. Cancer
Metab. 2014;2:19.
115. Azab AK, Sahin I, Moschetta M, et al. CXCR7-dependent angiogenic
mononuclear cell trafficking regulates tumor progression in multiple
myeloma. Blood. 2014;124(12):1905–1914.

Hypoxia

Publish your work in this journal
Hypoxia is an international, peer-reviewed, open access journal that aims
to improve understanding of the biological response to hypoxia. The
journal will publish original research articles, reviews, methodological
advances, clinical studies, and expert opinions that identify developments
in the regulation of the physiological and pathological responses to

116. Semenza GL. Cancer-stromal cell interactions mediated by hypoxiainducible factors promote angiogenesis, lymphangiogenesis, and
metastasis. Oncogene. 2013;32(35):4057–4063.
117. Lee CT, Mace T, Repasky EA. Hypoxia-driven immunosuppression:
a new reason to use thermal therapy in the treatment of cancer? Int J
Hyperthermia. 2010;26(3):232–246.
118. Noman MZ, Hasmim M, Messai Y, et al. Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses
to Hypoxia. Am J Physiol Cell Physiol. 2015;309(9):C569–C579.
119. Siemens DR, Hu N, Sheikhi AK, et al. Hypoxia increases tumor cell
shedding of MHC class I chain-related molecule: role of nitric oxide.
Cancer Res. 2008;68(12):4746–4753.
120. Yang M, Ma C, Liu S, et al. Hypoxia skews dendritic cells to a
T helper type 2-stimulating phenotype and promotes tumour cell migration by dendritic cell-derived osteopontin. Immunology. 2009;128
(1 Suppl):e237–e249.
121. Sitkovsky MV. T regulatory cells: hypoxia-adenosinergic suppression
and re-direction of the immune response. Trends Immunol. 2009;
30(3):102–108.
122. Rampling R, Cruickshank G, Lewis AD, Fitzsimmons SA, Workman P.
Direct measurement of pO2 distribution and bioreductive enzymes
in human malignant brain tumors. Int J Radiat Oncol Biol Phys.
1994;29(3):427–431.
123. Vaupel P, Schlenger K, Knoop C, Hockel M. Oxygenation of human
tumors: evaluation of tissue oxygen distribution in breast cancers
by computerized O2 tension measurements. Cancer Res. 1991;
51(12):3316–3322.
124. Lawrentschuk N, Poon AM, Foo SS, et al. Assessing regional hypoxia
in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int. 2005;96(4):540–546.
125. Leary TS, Klinck JR, Hayman G, Friend P, Jamieson NV, Gupta AK.
Measurement of liver tissue oxygenation after orthotopic liver transplantation using a multiparameter sensor. A pilot study. Anaesthesia.
2002;57(11):1128–1133.
126. Brooks AJ, Eastwood J, Beckingham IJ, Girling KJ. Liver tissue partial
pressure of oxygen and carbon dioxide during partial hepatectomy. Br
J Anaesth. 2004;92(5):735–737.
127. Le QT, Chen E, Salim A, et al. An evaluation of tumor oxygenation
and gene expression in patients with early stage non-small cell lung
cancers. Clin Cancer Res. 2006;12(5):1507–1514.
128. Koong AC, Mehta VK, Le QT, et al. Pancreatic tumors show high levels
of hypoxia. Int J Radiat Oncol Biol Phys. 2000;48(4):919–922.
129. Graffman S, Bjork P, Ederoth P, Ihse I. Polarographic pO2 measurements of intra-abdominal adenocarcinoma in connection with intraoperative radiotherapy before and after change of oxygen concentration
of anaesthetic gases. Acta Oncol. 2001;40(1):105–107.
130. Kallinowski F, Eble MJ, Buhr HJ, Wannenmacher M, Herfarth C.
Intraoperative radiotherapy for primary and recurrent rectal cancer.
Eur J Surg Oncol. 1995;21(2):191–194.

Dovepress
hypoxia and in the therapeutic targeting of hypoxia-responsive pathways.
The manuscript management system is completely online and includes
a very quick and fair peer-review system, which is all easy to use. Visit
http://www.dovepress.com/testimonials.php to read real quotes from
published authors.

Submit your manuscript here: http://www.dovepress.com/hypoxia-journal

92

submit your manuscript | www.dovepress.com

Dovepress

Hypoxia 2015:3

